Romanian Association against Leukemia (ARIL)’s mission is to improve the chances of recovery for current and future patients with hematological diseases in Romania by acting to improve treatment conditions. They put this into action by trying to find solutions for the problems patients identify and bring forward.
ARIL has recently turned its’ attention towards Human T-cell lymphotropic virus (HTLV), specifically HTLV-1. It is a proven etiologic agent of multiple disorders, and some individuals infected with HTLV-1 eventually develop an often rapidly fatal blood cancer (Adult T-cell leukemia/lymphoma).
ARIL has facilitated and supported the collaboration of HTLV specialists from five hospitals across Romania and France. These collaborations have produced promising new research in HTLV progression, diagnosis and treatment. In 2018, ARIL’s work in HTLV will focus on systematic patient tracking and database creation. “We would like to launch a project to verify how many patients actually have adult t-cell leukemia/lymphoma that began as HTLV-1.